- Home
- SAND vs ACAD Comparison
SAND vs ACAD Comparison
Compare SAND & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- ACAD
- Stock Information
- Founded
- SAND 2007
- ACAD 1993
- Country
- SAND Canada
- ACAD United States
- Employees
- SAND N/A
- ACAD N/A
- Industry
- SAND
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SAND
- ACAD Health Care
- Exchange
- SAND NYSE
- ACAD Nasdaq
- Market Cap
- SAND 2.4B
- ACAD 2.5B
- IPO Year
- SAND N/A
- ACAD 2004
- Fundamental
- Price
- SAND $8.81
- ACAD $17.44
- Analyst Decision
- SAND Buy
- ACAD Buy
- Analyst Count
- SAND 4
- ACAD 15
- Target Price
- SAND $9.13
- ACAD $24.21
- AVG Volume (30 Days)
- SAND 6.2M
- ACAD 1.7M
- Earning Date
- SAND 05-06-2025
- ACAD 05-07-2025
- Dividend Yield
- SAND 0.65%
- ACAD N/A
- EPS Growth
- SAND 32.83
- ACAD N/A
- EPS
- SAND 0.10
- ACAD 1.37
- Revenue
- SAND $183,537,000.00
- ACAD $996,283,000.00
- Revenue This Year
- SAND $16.62
- ACAD $13.07
- Revenue Next Year
- SAND $8.98
- ACAD $10.06
- P/E Ratio
- SAND $90.20
- ACAD $12.73
- Revenue Growth
- SAND 2.84
- ACAD 22.42
- 52 Week Low
- SAND $4.92
- ACAD $13.40
- 52 Week High
- SAND $8.82
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- SAND 63.60
- ACAD 67.70
- Support Level
- SAND $8.32
- ACAD $14.45
- Resistance Level
- SAND $8.91
- ACAD $15.31
- Average True Range (ATR)
- SAND 0.29
- ACAD 0.69
- MACD
- SAND -0.03
- ACAD 0.37
- Stochastic Oscillator
- SAND 89.39
- ACAD 94.92
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.